There remains a need for novel therapeutic strategies, such as a low-trehalose diet, for CDI treatment and prevention, and this is a potential area of future clinical investigation. The clinical benefit of such strategies should be proven before wide-scale changes to trehalose use in food manufacturing are undertaken.
Dual therapy with intravenous metronidazole and oral vancomycin is not superior to oral vancomycin alone in the treatment of Clostridioides difficile infections.
Toxin enzyme immunoassay more accurately identifies severe C difficile infections from strains more likely to cause recurrence, but otherwise had similar results for complications and mortality compared with the standard nucleic acid amplification test.
Patients with recurrent Clostridioides difficile infection (CDI) were less likely to develop bloodstream infections (BSI) if treated with fecal microbiota transplantation (FMT) compared with antibiotics.
Repeat testing of nucleic acid amplification tests is not recommended for detection of the presence of Clostridioides (formerly Clostridium) difficile in adults.
The use of a nucleic acid assay (NAAT) for diagnosing Clostridium difficile infection demonstrated a significant reduced length of stay (LOS) for patients compared with a multi-step enzyme immunoassay-based strategy, according to data presented at the American Society for Microbiology (ASM) Microbe 2019, held in San Francisco, California, from June 20 to 24, 2019. C…
The combination of vancomycin and fecal microbiota transplantation was found to be superior to fidaxomicin or vancomycin for patients with recurrent CDI.
Oral vancomycin is effective in preventing C difficile infection in allogeneic hematopoietic cell transplant patients and does not raise the risk for GVHD.
Patients admitted from the community who are hospitalized with Clostridioides (formerly Clostridium) difficile infection were more frequently discharged to a non-home location compared to patients without C difficile infection.
This study presents a simple, widely available and inexpensive model for predicting C difficile infection severity and mortality to identify patients at risk at admission to the ED.
